Mark-specific proportional hazards model with multivariate continuous marks and its application to HIV vaccine efficacy trials

被引:6
|
作者
Sun, Yanqing [2 ]
Li, Mei [1 ]
Gilbert, Peter B. [3 ,4 ]
机构
[1] Zhejiang Univ, Sch Publ Hlth, Hangzhou 310003, Zhejiang, Peoples R China
[2] Univ N Carolina, Dept Math & Stat, Charlotte, NC 28223 USA
[3] Univ Washington, Dept Biostat, Seattle, WA 98109 USA
[4] Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA
基金
美国国家卫生研究院; 美国国家科学基金会;
关键词
Competing risks; Failure time data; Goodness-of-fit test; HIV vaccine trial; Hypothesis testing; Mark-specific relative risk; Multivariate data; Partial likelihood estimation; Semiparametric model; STEP trial; DOUBLE-BLIND; COEFFICIENTS; TIME; STEP;
D O I
10.1093/biostatistics/kxs022
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
For time-to-event data with finitely many competing risks, the proportional hazards model has been a popular tool for relating the cause-specific outcomes to covariates (Prentice and others, 1978. The analysis of failure time in the presence of competing risks. Biometrics 34, 541-554). Inspired by previous research in HIV vaccine efficacy trials, the cause of failure is replaced by a continuous mark observed only in subjects who fail. This article studies an extension of this approach to allow a multivariate continuum of competing risks, to better account for the fact that the candidate HIV vaccines tested in efficacy trials have contained multiple HIV sequences, with a purpose to elicit multiple types of immune response that recognize and block different types of HIV viruses. We develop inference for the proportional hazards model in which the regression parameters depend parametrically on the marks, to avoid the curse of dimensionality, and the baseline hazard depends nonparametrically on both time and marks. Goodness-of-fit tests are constructed based on generalized weighted martingale residuals. The finite-sample performance of the proposed methods is examined through extensive simulations. The methods are applied to a vaccine efficacy trial to examine whether and how certain antigens represented inside the vaccine are relevant for protection or anti-protection against the exposing HIVs.
引用
收藏
页码:60 / 74
页数:15
相关论文
共 11 条